Scout | Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed)

This funding opportunity aims to support research on the connections between certain genetic regions (HLA and KIR) and diseases that are influenced by the immune system. The goals are to understand these connections better, explore the mechanisms behind them to find new treatments, and confirm these connections to enhance disease prediction in clinical settings.

Source

Agency: National Institutes of Health

Program: SBIR

Award

Award Ceiling: $400,000

Funding Amount: $400,000

Dates

Opportunity Released: April 23, 2024

Open for Submission: April 23, 2024

Submission Deadline: August 20, 2024

Application Window Closes: August 20, 2024

Keywords

HLA

KIR

genomics

immune-mediated diseases

genetic associations

therapeutic opportunities

predictive screening

clinical research

immunogenetics

disease mechanisms

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers